IPO Year: 2024
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/21/2025 | $60.00 | Buy | BTIG Research |
2/25/2025 | $50.00 → $55.00 | Overweight → Neutral | Analyst |
2/12/2025 | Outperform → Mkt Perform | William Blair | |
2/5/2025 | $58.00 → $74.00 | Buy | TD Cowen |
12/13/2024 | $60.00 | Outperform | Wolfe Research |
12/9/2024 | $74.00 | Buy | Guggenheim |
11/11/2024 | $45.00 → $65.00 | Buy → Hold | Stifel |
10/2/2024 | $45.00 → $60.00 | Buy → Neutral | BofA Securities |
8/12/2024 | $40.00 | Neutral | Piper Sandler |
7/9/2024 | $41.00 | Buy | BofA Securities |
8-K - Tempus AI, Inc. (0001717115) (Filer)
144 - Tempus AI, Inc. (0001717115) (Subject)
144 - Tempus AI, Inc. (0001717115) (Subject)
144 - Tempus AI, Inc. (0001717115) (Subject)
SCHEDULE 13G/A - Tempus AI, Inc. (0001717115) (Subject)
144 - Tempus AI, Inc. (0001717115) (Subject)
SCHEDULE 13G/A - Tempus AI, Inc. (0001717115) (Subject)
424B3 - Tempus AI, Inc. (0001717115) (Filer)
10-Q - Tempus AI, Inc. (0001717115) (Filer)
8-K - Tempus AI, Inc. (0001717115) (Filer)
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13D - Tempus AI, Inc. (0001717115) (Filed by)
NOTE TO EDITORS: The Following is an Investment Opinion Issued by Spruce Point Capital Management Warns That Tempus Management and Board Members Have a History Together of Promoting Disruptive Technology Companies Which Have Frequently Resulted in Financial Restatements and Shareholder Losses Expresses Concerns About Tempus' Artificial Intelligence Capabilities Given Minimal Revenues and Product Demonstrations, Which Appear to Show Irreconcilable Inputs Questions the Quality of Revenues and Adjusted EBITDA Based on Related Party Dealings, Investments That Become Revenue Generating Customers, and Accounting Choices Related to Debt That Flatter Operating Income Believes That Recent Ac
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its participation in almost 1,500 research projects in just the last ten years. This milestone highlights Tempus' ongoing commitment to accelerating scientific discovery and delivering data-driven insights that improve patient outcomes. Since its founding in 2015, Tempus has partnered with leading academic institutions, community health systems, and biopharma organizations to drive forward cutting-edge research and advance precision medicine. Leveraging its AI-powered platform, Tempus offers one of the most comprehensive suites of solutions supporti
Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ:TEM), and a leader in clinical genomic testing, today announced the publication of a study in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG). The study reveals the potentially transformative impact of Ambry Genetics' Patient for Life™ program, which systematically reanalyzes data from the company's database of exome test results. By reclassifying genetic variants based on newly discovered gene-disease associations and emerging evidence supporting variant path
Surging demand for 2X Leveraged Daily ETFs tied to D-Wave Quantum, Tempus AI & AppLovin now met with expanded trading flexibility NEW YORK, May 21, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, today announced that options trading is now available on its newest three leveraged ETFs: Tradr 2X Long QBTS Daily ETF (Cboe: QBTX), Tradr 2X Long TEM Daily ETF (Cboe: TEMT), and Tradr 2X Long APP Daily ETF (NASDAQ:APPX). The three ETFs, all first-to-market products, have quickly gained traction among traders seeking 200% daily long exposure to highly followed, liquid single names involved in emerging technology: D-Wave Quantum (NYSE
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the William Blair 45th Annual Growth Stock Conference. The event will take place from June 3-5 in Chicago, IL. Jim Rogers, Chief Financial Officer of Tempus, will present on June 5. A live audio webcast of the presentation will be available here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a companion diagnostic (CDx) test with Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers. Tempus completed confirmatory testing in Verastem's Phase 2 RAMP-201 clinical trial, which evaluated the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian cancer (LGSOC) and was the basis of the recent U.S. Food and Drug Administration's (FDA) accelerated approval of the combination in KRAS-mutated recur
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new strategic collaboration to advance Boehringer Ingelheim's growing cancer pipeline. The new, multi-year collaboration builds on foundational work the two companies have conducted in the last few years, leveraging data and AI to further advance therapeutic research and development. Despite significant breakthroughs in the understanding, prevention, and treatment of cancer, the disease remains a major challenge, impacting millions of lives and straining healthcare systems. Boehringer Ingelheim is committed to changing this by advancing the discove
TEMT offers 2X daily exposure to an exciting AI-driven, tech-health story NEW YORK, May 13, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, today announced the launch of a new single stock leveraged ETF, the Tradr 2X Long TEM Daily ETF (Cboe: TEMT). The fund aims to deliver twice (200%) the daily performance of the common stock of Tempus AI, Inc. (NASDAQ:TEM), a technology company advancing precision medicine through the practical application of artificial intelligence, including generative AI, in healthcare. Traders who are bullish on Tempus can utilize Tradr ETFs' new fund to take advantage of swings in TEM's daily stock pr
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 5, 2025 /PRNewswire/ --The integration of artificial intelligence (AI) into healthcare is here to stay, and adoption is accelerating. According to research from PYMNTS Intelligence which polled C-suite executives at healthcare companies generating at least $1 billion in annual revenue, 90% already see positive ROI from investments in generative AI (GenAI). Analysts are projecting that by 2035 the gross value added by AI to the healthcare industry will be $461 billion on top of a baseline $2.26 trillion. Behind the scenes, several new AI healthcare tech developments are taking place, with updates rec
BTIG Research initiated coverage of Tempus AI with a rating of Buy and set a new price target of $60.00
Analyst downgraded Tempus AI from Overweight to Neutral and set a new price target of $55.00 from $50.00 previously
William Blair downgraded Tempus AI from Outperform to Mkt Perform
TD Cowen resumed coverage of Tempus AI with a rating of Buy and set a new price target of $74.00 from $58.00 previously
Wolfe Research initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $60.00
Guggenheim initiated coverage of Tempus AI with a rating of Buy and set a new price target of $74.00
Stifel downgraded Tempus AI from Buy to Hold and set a new price target of $65.00 from $45.00 previously
BofA Securities downgraded Tempus AI from Buy to Neutral and set a new price target of $60.00 from $45.00 previously
Piper Sandler initiated coverage of Tempus AI with a rating of Neutral and set a new price target of $40.00
BofA Securities initiated coverage of Tempus AI with a rating of Buy and set a new price target of $41.00
4 - Tempus AI, Inc. (0001717115) (Reporting)
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4680302 Domestic Dial-in Number: (800) 715-9871 International Dial-in Number: (646) 307
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 9601821 Domestic Dial-in Number: (888) 596-4144 International Dial-i
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The company's conference call that was previously scheduled for November 7, 2024 has been canceled. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursday, November 7, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7177136 Domestic Dial-in Number: (800) 715-9871 International Dial-in
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesday, August 6, 2024. The company will hold the second quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 6326328 Domestic Dial-in Number: (800) 715-9871 International Dial-in
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)